| Inflammatory bowel disease and mutations affecting the interleukin-10 receptor EO Glocker, D Kotlarz, K Boztug, EM Gertz, AA Schäffer, F Noyan, M Perro, ... New England Journal of Medicine 361 (21), 2033-2045, 2009 | 1663 | 2009 |
| Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors P Lito, A Saborowski, J Yue, M Solomon, E Joseph, S Gadal, ... Cancer cell 25 (5), 697-710, 2014 | 314 | 2014 |
| A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14 G Bohn, A Allroth, G Brandes, J Thiel, E Glocker, AA Schäffer, C Rathinam, ... Nature medicine 13 (1), 38-45, 2007 | 215 | 2007 |
| Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins MA Davare, A Saborowski, CA Eide, C Tognon, RL Smith, J Elferich, ... Proceedings of the National Academy of Sciences 110 (48), 19519-19524, 2013 | 152 | 2013 |
| Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry L Izquierdo-Sanchez, A Lamarca, A La Casta, S Buettner, K Utpatel, ... Journal of hepatology 76 (5), 1109-1121, 2022 | 148 | 2022 |
| Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma A Vogel, A Saborowski Cancer treatment reviews 82, 101946, 2020 | 131 | 2020 |
| Identification of a homozygous deletion in the AP3B1 gene causing Hermansky-Pudlak syndrome, type 2 J Jung, G Bohn, A Allroth, K Boztug, G Brandes, I Sandrock, AA Schäffer, ... Blood 108 (1), 362-369, 2006 | 130 | 2006 |
| Mouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic target A Saborowski, M Saborowski, MA Davare, BJ Druker, DS Klimstra, ... Proceedings of the National Academy of Sciences 110 (48), 19513-19518, 2013 | 84 | 2013 |
| Dual role of the adaptive immune system in liver injury and hepatocellular carcinoma development J Endig, LE Buitrago-Molina, S Marhenke, F Reisinger, A Saborowski, ... Cancer cell 30 (2), 308-323, 2016 | 76 | 2016 |
| A modular and flexible ESC-based mouse model of pancreatic cancer M Saborowski, A Saborowski, JP Morris, B Bosbach, LE Dow, J Pelletier, ... Genes & development 28 (1), 85-97, 2014 | 75 | 2014 |
| Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience T de Castro, LS Jochheim, M Bathon, S Welland, B Scheiner, K Shmanko, ... Therapeutic Advances in Medical Oncology 14, 17588359221080298, 2022 | 51 | 2022 |
| Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells Z Dai, G Song, A Balakrishnan, T Yang, Q Yuan, S Möbus, AC Weiss, ... Gut 69 (6), 1104-1115, 2020 | 51 | 2020 |
| Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma G Kendre, K Murugesan, T Brummer, O Segatto, A Saborowski, A Vogel Journal of hepatology 78 (3), 614-626, 2023 | 48 | 2023 |
| FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next? A Saborowski, U Lehmann, A Vogel Therapeutic Advances in Medical Oncology 12, 1758835920953293, 2020 | 40 | 2020 |
| Murine Liver Organoids as a Genetically Flexible System to Study Liver Cancer In Vivo and In Vitro A Saborowski, K Wolff, S Spielberg, B Beer, B Hartleben, Z Erlangga, ... Hepatology communications 3 (3), 423-436, 2019 | 36 | 2019 |
| 53MO Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio-and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC–AIO-HEP-0116) A Vogel, P Wenzel, G Folprecht, P Schütt, H Wege, A Kretzschmar, ... Annals of Oncology 33, S563-S564, 2022 | 34 | 2022 |
| Immunotherapies in clinical development for biliary tract cancer A Vogel, M Bathon, A Saborowski Expert Opinion on Investigational Drugs 30 (4), 351-363, 2021 | 34 | 2021 |
| Cholangiocellular carcinoma A Vogel, A Saborowski Digestion 95 (3), 181-185, 2017 | 33 | 2017 |
| Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma S Vicent, R Lieshout, A Saborowski, MMA Verstegen, C Raggi, ... Liver International 39, 79-97, 2019 | 32 | 2019 |
| The changing landscape of systemic treatment of advanced hepatocellular carcinoma: new targeted agents and immunotherapies JU Marquardt, A Saborowski, C Czauderna, A Vogel Targeted Oncology 14, 115-123, 2019 | 26 | 2019 |
